Back to top
more

Pfizer (PFE)

(Delayed Data from NYSE)

$29.09 USD

29.09
25,001,151

+0.12 (0.41%)

Updated Sep 27, 2024 04:02 PM ET

After-Market: $29.09 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value F Growth D Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 18% (45 out of 251)

Industry: Large Cap Pharmaceuticals

Better trading starts here.

Zacks News

Pfizer (PFE) Stock Sinks As Market Gains: What You Should Know

In the latest trading session, Pfizer (PFE) closed at $41.32, marking a -0.41% move from the previous day.

PFE vs. LLY: Which Stock Should Value Investors Buy Now?

PFE vs. LLY: Which Stock Is the Better Value Option?

Pfizer (PFE) Gets CHMP Nod for JAK Inhibitor Abrocitinib

The CHMP recommends approving Pfizer (PFE) JAK inhibitors abrocitinib and Xeljanz for the treatment of atopic dermatitis and active ankylosing spondylitis, respectively.

J&J, Moderna COVID-19 Booster Jabs Near FDA Authorization

The FDA's Vaccines and Related Biological Products advisory committee recommends emergency use authorization for booster doses of J&J and Moderna's COVID-19 vaccines for use in certain adults.

J&J (JNJ) to Start Q3 Earnings Season for Pharma Sector

J&J's (JNJ) Pharma segment is expected to have performed above market while market recovery might have benefited Medical Devices segment sales in the third quarter.

Novavax (NVAX) Lags in COVID Vaccine Race: Will It Gather Pace?

Novavax (NVAX) is progressing well with its COVID-19 and flu vaccines. However, it is lagging in the COVID-19 vaccine space. Let us see how the company is likely to perform going forward.

Deciphera (DCPH) Thrives on Qinlock, Overdependence a Woe

Deciphera's (DCPH) Qinlock is approved for treating advanced gastrointestinal stromal tumors. The drug has seen solid uptake since its launch. Heavy dependence on Qinlock for growth remains a concern.

Clovis (CLVS) Focuses on Rubraca Growth Amid Rising Competition

Clovis Oncology's (CLVS) sole marketed drug Rubraca has been approved for multiple cancer indications. Yet, the drug's sales remain tepid on account of competition from PARP inhibitors.

The Zacks Analyst Blog Highlights: Southwest Airlines, Delta Air Lines, Moderna, Pfizer and BioNTech

The Zacks Analyst Blog Highlights: Southwest Airlines, Delta Air Lines, Moderna, Pfizer and BioNTech

Mark Vickery headshot

Best Single Trading Day in Months for Dow, Nasdaq, S&P

The indexes had been trying to turn around a steep drop to the start of the week, and finally managed on Thursday.

Has Pfizer (PFE) Outpaced Other Medical Stocks This Year?

Is (PFE) Outperforming Other Medical Stocks This Year?

Epizyme's (EPZM) Tazverik Aids Growth, Overdependence a Woe

While Epizyme (EPZM) gets a significant boost with the approval of Tazverik for the treatment of follicular lymphoma and epithelioid sarcoma, the sole dependence on Tazverik for growth remains a woe.

Novavax (NVAX) Concentrates on COVID-19 Vaccine Development

While Novavax's (NVAX) COVID-19 vaccine shows potential, delay in regulatory filings in both the United States and Europe does not bode well for the stock.

Will Moderna's (MRNA) COVID-Led Rally Continue in 2022?

Moderna's (MRNA) COVID-19 vaccine has boosted the company's prospects significantly since early 2020. Strong performance of the vaccine is likely to continue in 2022. However, competition seems to be on the rise.

Incyte's (INCY) Going Gets Rough Despite Recent Approvals

Incyte (INCY) recent drug approvals fail to impress investors due to the FDA's warnings about increased risks of serious heart-related events, cancer, blood clots, and death for JAK inhibitors.

Should Invesco S&P Ultra Dividend Revenue ETF (RDIV) Be on Your Investing Radar?

Style Box ETF report for RDIV

Merck (MRK) Seeks Emergency Nod for Oral Antiviral COVID-19 Pill

Merck's (MRK) molnupiravir to be the first oral antiviral medicine for the treatment of COVID-19, if authorized by the FDA.

Mark Vickery headshot

Pre-Markets Back to Green Ahead of Economic & Earnings Data

After a down day yesterday, we see the Dow +30 points, the S&P 500 +3 points and the Nasdaq +33.

Markets Await Economic and Earnings Data

Markets Await Economic and Earnings Data

Pfizer (PFE) Dips More Than Broader Markets: What You Should Know

Pfizer (PFE) closed at $42.06 in the latest trading session, marking a -0.92% move from the prior day.

Pfizer (PFE) is a Top-Ranked Growth Stock: Should You Buy?

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

The Zacks Analyst Blog Highlights: Pfizer, American Tower Corp, Intuitive Surgical, Fidelity National Information Services and FedEx

The Zacks Analyst Blog Highlights: Pfizer, American Tower Corp, Intuitive Surgical, Fidelity National Information Services and FedEx

Is Principal U.S. MegaCap ETF (USMC) a Strong ETF Right Now?

Smart Beta ETF report for USMC

Mark Vickery headshot

Top Analyst Reports for Pfizer, American Tower & Intuitive Surgical

Today's Research Daily features new research reports on 16 major stocks, including Pfizer Inc. (PFE), American Tower Corporation (AMT), and Intuitive Surgical, Inc. (ISRG).

Cousins Properties' (CUZ) Heights Union Buyout Fails to Drive Stock

The acquisition of Heights Union is in line with Cousins Properties' (CUZ) efforts to enhance its portfolio quality with trophy assets.